These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 3116917)

  • 1. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance.
    Blaser J; Stone BB; Groner MC; Zinner SH
    Antimicrob Agents Chemother; 1987 Jul; 31(7):1054-60. PubMed ID: 3116917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model.
    Blaser J; Stone BB; Zinner SH
    Antimicrob Agents Chemother; 1985 Mar; 27(3):343-9. PubMed ID: 3922294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro activities of enoxacin (CI-919, AT-2266) and eleven antipseudomonal agents against aminoglycoside-susceptible and -resistant Pseudomonas aeruginosa strains.
    Bassey CM; Baltch AL; Smith RP; Conley PE
    Antimicrob Agents Chemother; 1984 Sep; 26(3):417-8. PubMed ID: 6439116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose.
    Well M; Naber KG; Kinzig-Schippers M; Sörgel F
    Int J Antimicrob Agents; 1998 Apr; 10(1):31-8. PubMed ID: 9624541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of medium and method on the in vitro susceptibility of Pseudomonas aeruginosa and other bacteria to ciprofloxacin and enoxacin.
    Blaser J; Dudley MN; Gilbert D; Zinner SH
    Antimicrob Agents Chemother; 1986 May; 29(5):927-9. PubMed ID: 2942102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of enoxacin compared with norfloxacin and amikacin.
    van der Auwera P; de Moor G; Lacroix G; Mambour A; Rossion N; Schuyteneer F
    Eur J Clin Microbiol; 1985 Feb; 4(1):55-8. PubMed ID: 3157568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of once- and thrice-daily dosing of aminoglycosides in in-vitro models of infection.
    Blaser J
    J Antimicrob Chemother; 1991 May; 27 Suppl C():21-8. PubMed ID: 1906863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compiled data on aminoglycoside, foremost netilmicin susceptibility of bacterial strains.
    Juhlin I; Tunevall G
    Scand J Infect Dis Suppl; 1980; Suppl 23():39-44. PubMed ID: 6782657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-vitro studies of antibiotic combinations with special emphasis on the evaluation of newly developed methods.
    Zinner SH; Blaser J
    J Antimicrob Chemother; 1986 Mar; 17 Suppl A():1-5. PubMed ID: 3086275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibacterial activity of enoxacin: comparison with aminoglycosides, beta-lactams and other antimicrobial agents.
    Vanhoof R; Hubrechts JM; Roebben E; Claeys M; Nyssen HJ
    J Antimicrob Chemother; 1986 Mar; 17(3):297-302. PubMed ID: 3457785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enoxacin-induced modification of the susceptibility of bacteria to phagocytic killing.
    Pruul H; Kriek G; McDonald PJ
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():19-27. PubMed ID: 3129391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enoxacin: in-vitro and animal evaluation as a parenteral and oral agent against hospital bacterial isolates.
    Heifetz CL; Bien PA; Cohen MA; Dombrowski ME; Griffin TJ; Malta TE; Sesnie JC; Shapiro MA; Wold SA
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():29-42. PubMed ID: 3129392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of netilmicin, gentamicin, and amikacin.
    Kantor RJ; Norden CW
    Antimicrob Agents Chemother; 1977 Jan; 11(1):126-31. PubMed ID: 402104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of leucocyte killing of resistant bacteria selected during exposure to aminoglycosides or quinolones.
    Schlaeffer F; Blaser J; Laxon J; Zinner S
    J Antimicrob Chemother; 1990 Jun; 25(6):941-8. PubMed ID: 2115038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of netilmicin regimens on the activities of ceftazidime-netilmicin combinations against Pseudomonas aeruginosa in an in vitro pharmacokinetic model.
    Blaser J; Stone BB; Groner MC; Zinner SH
    Antimicrob Agents Chemother; 1985 Jul; 28(1):64-8. PubMed ID: 3929682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
    Guimaraes MA; Noone P
    J Antimicrob Chemother; 1986 Jan; 17(1):63-7. PubMed ID: 2936708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents.
    Wise R; Andrews JM; Danks G
    J Antimicrob Chemother; 1984 Mar; 13(3):237-44. PubMed ID: 6586712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim.
    Chin NX; Neu HC
    Antimicrob Agents Chemother; 1983 Nov; 24(5):754-63. PubMed ID: 6229216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enoxacin: a potent inducer of filamentous Escherichia coli cells (a note).
    Uri JV; Actor P
    Acta Microbiol Hung; 1985; 32(2):197-200. PubMed ID: 3933273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low frequency of bacterial resistance to enoxacin in vitro and in experimental pneumonia.
    Scribner RK; Welch DF; Marks MI
    J Antimicrob Chemother; 1985 Nov; 16(5):597-603. PubMed ID: 3865924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.